Society of Hematologic Oncology (SOHO) session to highlight volasertib program Phase 2 volasertib AML program expected to begin in the coming months FOSTER CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that the Company will present an overview of the Phase 2 program and additional data fro ...

Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that Thomas A. Bock, MD has resigned from his positions as Chief Executive Of ...

"We are pleased to report positive progress in our clinical development program to evaluate the use of volasertib, in combination with decitabine, for patients with R/R AML. Receiving FDA's clearance and agreement on a Phase 2 dosing plan positions us to move forward to activate study sites," said Thomas Bock, M.D., Chief Executive Officer of Notable. "AML remains a devastating and life-threatening unmet need, especially for patients whose disease has progressed after first-line treatment, and especially in ...

Shares of Notable Labs (NTBL) have been struggling lately and have lost 22.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road. While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future ear ...

Clinical Development - Notable's Predictive Precision Medicines Platform (PPMP) achieved a clinical response prediction accuracy of 83-100% in four independent trials[81]. - The company plans to initiate a Phase 2 trial for its lead asset Volasertib in adult acute myeloid leukemia (AML) in Q2 2024, with results expected in Q4 2024[84]. - Notable anticipates significant increases in research and development expenses as it prepares for late-stage clinical studies and regulatory approvals for Volasertib and Fosciclopirox[94]. - The company does not expect to generate product revenue until regulatory approval for Volasertib or Fosciclopirox is obtained[109]. - The company anticipates significant and increasing operating losses in 2024 as it advances clinical development efforts[109]. Financial Performance - For the three months ended March 31, 2024, Notable reported services revenue of $1 thousand, an increase from $0 in the same period of 2023[99]. - Research and development expenses for the three months ended March 31, 2024, were $1.55 million, a decrease of $46 thousand compared to $1.60 million in the same period of 2023[100]. - General and administrative expenses decreased by $1.63 million to $2.29 million for the three months ended March 31, 2024, compared to $3.92 million in the same period of 2023[98]. - The net loss for the three months ended March 31, 2024, was $3.77 million, a reduction of $2.51 million from a net loss of $6.27 million in the same period of 2023[98]. - Net loss decreased to $3.8 million from $6.3 million, a decrease of $2.5 million or 40.0% for the three months ended March 31, 2024 compared to the same period in 2023[106]. - Other income increased to $0.1 million from a net expense of $0.7 million, an increase of $0.8 million or 109.6% for the three months ended March 31, 2024 compared to the same period in 2023[105]. - Cash used in operating activities was $3.6 million for the three months ended March 31, 2024, an increase of approximately 21.8% from $2.9 million in the same period in 2023[117]. - The company has an accumulated deficit of $86.1 million as of March 31, 2024, primarily due to development efforts[107]. - Net cash used in financing activities was $0 million for the three months ended March 31, 2024, a decrease of $4.3 million from $4.3 million provided in the same period in 2023[119]. Funding and Financial Strategy - Following the merger on October 16, 2023, former Notable Labs, Inc. equity holders owned approximately 71.9% of the outstanding equity of the company[86]. - The merger was treated as a reverse recapitalization, with Notable Labs, Inc. being the accounting acquirer[87]. - The company plans to seek additional funding through public or private offerings, debt financing, or collaborations to meet operational needs[111]. - As of May 9, 2024, the company has cash and cash equivalents of $6.8 million, which is expected to finance operations through September 2024[108]. Revenue Recognition - Notable recognizes revenue from diagnostic services based on a five-step revenue recognition model[131]. - As of March 31, 2024, and December 31, 2023, Notable has not recorded any deferred revenue or contract assets[131]. - Notable has not received any advance payments for which there are remaining performance obligations[131]. - Material costs of services revenue are recorded as costs of sales, while immaterial costs are recorded in operating expenses[131]. - Revenue is recognized when performance obligations are satisfied by transferring promised goods or services to customers[132].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Israel 001-36581 Not Applicable (IRS Employer Identification No.) 320 Hatch Drive Foster City, California 94404 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (415) 851-2410 N/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2024 NOTABLE LABS, LTD. (Exact name of registrant as ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ____. Commission file number 001-36581 NOTABLE LABS, LTD. (Exact name of registrant as specified in its charter) Israel Not applicable (State or other juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-36581 Notable Labs, Ltd. (Exact name of registrant as specified in its charter) Israel No ...

Revenue and Financial Performance - The company generated cumulative revenues of approximately $17.4 million, primarily from an exclusive license agreement with NanoCarrier Co., Ltd., which has now been terminated [77]. - No revenues were recorded for the three and six months ended June 30, 2023, compared to $0.1 million and $0.2 million for the same periods in 2022, respectively, due to the termination of the NanoCarrier license agreement [91][93]. - The company recorded a gain on the sale of its former Modi'in manufacturing facility of approximately $0.4 million during the six months ended June 30, 2023 [72]. - Cash used in operating activities was approximately $4.1 million for the six months ended June 30, 2023, compared to $18.1 million for the same period in 2022, indicating a significant reduction in cash burn [111][112]. - As of June 30, 2023, the company had cash and cash equivalents totaling $24.3 million and working capital of $19.2 million, which is expected to be sufficient to fund operations for at least 12 months [107]. Expenses and Cost Management - Research and development expenses are expected to be significantly less than prior periods due to the closure of the ofra-vec program and the early stage of the VB-601 program [84]. - Research and development expenses, net, decreased by approximately $8.3 million for the three months ended June 30, 2023, and by approximately $15.7 million for the six months ended June 30, 2023, primarily due to the termination of clinical trials and workforce reductions [95][96]. - General and administrative expenses are expected to decrease due to a significant reduction in workforce, although legal and administrative fees related to the merger are anticipated to increase [85]. - General and administrative expenses decreased by $1.1 million for the three months ended June 30, 2023, and by $1.0 million for the six months ended June 30, 2023, mainly due to reversals of share-based compensation and reduced payroll expenses [97][98]. - Operating loss for the three months ended June 30, 2023, was $0.9 million, compared to an operating loss of $9.6 million for the same period in 2022, reflecting a decrease of $8.7 million [90]. - Impairment loss for the three and six months ended June 30, 2023, was $0.3 million, attributed to the write-down of remaining fixed assets in preparation for a merger [99][100]. Mergers and Acquisitions - The proposed sale of the VB-601 asset includes total cash consideration of up to $5 million plus royalties, with an upfront cash payment of $250,000 upon closing [73]. - The merger with Notable Labs, Inc. is expected to result in former Notable securityholders owning approximately 76% of the ordinary shares on a fully diluted basis [69]. - The merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes [68]. - The company plans to use proceeds from the asset sale to meet the $15.0 million minimum net cash closing condition required by the merger agreement [72]. Funding and Grants - The company has received a total of $38.4 million in grants from the Israeli Innovation Authority, which are subject to repayment through future royalty payments [82]. - The company raised an aggregate of $328.5 million since inception, including $29.4 million from IIA grants and $2.6 million from the EIC [106]. - The company anticipates needing additional capital to obtain regulatory approval for product candidates and may pursue various financing options, including equity offerings and collaborations [108]. Compliance and Regulatory Matters - The company has a compliance period until August 28, 2023, to regain compliance with Nasdaq's minimum bid price requirement [74]. - Financial expenses, net, were approximately $0.01 million for the three months ended June 30, 2023, compared to $0.2 million of income for the same period in 2022, primarily due to changes in exchange rates [104].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-36581 Vascular Biogenics Ltd. (Exact name of registrant as specified in its charter) Israel ...